WO2015183213A1 - Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid - Google Patents
Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid Download PDFInfo
- Publication number
- WO2015183213A1 WO2015183213A1 PCT/TR2014/000494 TR2014000494W WO2015183213A1 WO 2015183213 A1 WO2015183213 A1 WO 2015183213A1 TR 2014000494 W TR2014000494 W TR 2014000494W WO 2015183213 A1 WO2015183213 A1 WO 2015183213A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glutamic acid
- amino
- methyl
- benzoyl
- pteridinyl
- Prior art date
Links
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 title claims abstract description 22
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 title claims abstract description 21
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title claims abstract description 18
- -1 2-amino-3,4- dihydro -4-oxo-6- pteridinyl Chemical group 0.000 title claims abstract description 13
- 229960002989 glutamic acid Drugs 0.000 title claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims abstract description 12
- 239000002552 dosage form Substances 0.000 title claims description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims abstract description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 6
- 239000011734 sodium Substances 0.000 claims abstract description 6
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 6
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 150000004682 monohydrates Chemical class 0.000 claims abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- 239000006172 buffering agent Substances 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 229940071643 prefilled syringe Drugs 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims description 2
- 229940124274 edetate disodium Drugs 0.000 claims description 2
- 229960001484 edetic acid Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 claims description 2
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 206010069162 Gasping syndrome Diseases 0.000 claims 1
- GFVMLYBCWPLMTF-UHFFFAOYSA-N disodiomagnesium Chemical compound [Na][Mg][Na] GFVMLYBCWPLMTF-UHFFFAOYSA-N 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 238000009517 secondary packaging Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 32
- 239000008186 active pharmaceutical agent Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 11
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 239000003182 parenteral nutrition solution Substances 0.000 description 9
- 239000008215 water for injection Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- 238000011049 filling Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012369 In process control Methods 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000010965 in-process control Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000013618 particulate matter Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- TZBGSHAFWLGWBO-ABLWVSNPSA-N (2s)-2-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl)methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NCC1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-ABLWVSNPSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000005095 gastrointestinal system Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003684 drug solvent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000012027 sterile manufacturing Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Definitions
- the invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
- API II N-[4-[[(2- Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) (hereafter refer to as API II) or pharmaceutically acceptable salts,particulary
- API I
- the formulation of the invention relates to a pharmaceutical dosage form and its combination which is not exist in Turkey and the world.
- EP2046332 describes using 50 mg/ml methotrexate for the treatment of inflammatory autoimmune diseases.
- EP2046813 describes protein binding methotrexate derivatives and pharmaceutical compositions comprising the methotrexate derivatives.
- the formulation of the protein binding methotrexate derivative is intended to be used for the treatment of cancer and rheumatic disease.
- the structural formula which mentioned in the independent claim will be explained in detail in the following;
- the object of the invention is to provide the use of the most stable pharmaceutical dosage forms that containing API I and API II combination,indicating a long shelf life, used for preventive and therapeutic purpose,increasing patient compliance.
- the invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
- API I is an antineoplastic drug. However, it is used to treat many other diseases unrelated with cancer in lower doses. It is being used via intravenous and higher doses are being used to treat cancer.
- API I is a cycle specific drug that is showing both antineoplastic and immunosuppressant activity .As an antimetabolite it inhibits dihydrofolate reductase enzyme which is responsible for reduction of API II to tetrahydro structure . Reduction of tetrahydro API II decreases the required level of one-carbon groups and accordingly, purines' ,DNA's and cellular protein synthesis is inhibited.
- API I is being administered by orally and intravenously. It is well absorbed when given as a low single dose (below 50mg / ml). The absorption is irregular when given above this dosage and it is suitable administering in divided doses. It is completely absorbed when administered by intramuscular injection.
- BP British Pharmacopoeia
- USP American Pharmacopoeia
- API II is a water soluble vitamin B-complex used for oral and parenteral administration. Deficiency can cause various hematological complications including megaloblastic anemia.
- API II is a biochemically inactive compound that it is precursor of tetrahydrofolic acid and methyltetrahydrofolate. Tetrahydrofolic acid, methyltetrahydrofolate and other folic acid derivatives are necessary substances to sustain erythropoiesis normally. These substances are needed as cofactors for the synthesis of purine and thymidylate nucleic acid. API II and its derivatives are necessary for the conversion of amino acids to each other. API II is given by oral and parenteral administration. Peak levels have been seen within 1 hour.
- API II is yellow to orange-brown coloured, odorless or very lightly scented crystalline powder.
- BP British Pharmacopoeia
- US Pharmacopeia US Pharmacopeia
- it is very slightly soluble in water; insoluble in alcohol, acetone, chloroform and ether; rapidly soluble in dilute solutions of alkali hydroxides and carbonates; soluble in hydrochloric acid and sulfuric acid.
- pH range of solution for injection is 8-1 1. It must be protected from light and avoided freezing.
- Parenteral drugs are given to circulatory system directly or indirectly excepting gastrointestinal system with a syringe as a sterile single dose or multi-dose form of ready to use syringe or vial.
- the pharmaceutical form is containing N- [4 - [[(2,4-Diamino-6- pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid (or N- [4 - ((2,4-Diaminopteri pyrimidin-6- ylmethyl) methylamino) benzoyl] -L (+) - glutamic acid) and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo,-6-pteridinyl) methyl] methylamino] benzoyl] -L -glutamic acid (or N- (4- (2-Amino-4-hidroksipteridin-6-ylmethylamino) benzoyl)
- Production of parenteral solution is comprising the production of small volume parenteral of different volumes of liquid dosage form.
- Production of parenteral drug can be carried out in the fully automated production line named ready to use syringe filling line.
- Parenteral solutions are filled into sterile pre-filled syringe, vial or PVC containers.They are administered by injection .
- parenteral solutions may also be called injectable solutions.
- injectable solutions must be sterile.
- the pH of the solution must be equal or close to the pH of body fluids (7.4).
- Osmolality of the solution must be isosmotic with body fluids or close to them.
- lt must not contain pyrogen which has bacterial lipopolysaccharide structure and can cause fever (should be apyrogenic ).
- the solution must not contain particulate matter (micro or macroparticle).
- Parenteral treatment is administering therapeutic agents by other than gastrointestinal system.
- fluid and electrolytes, vitamins, sugars, protein, blood or components, vaccines, several drugs for therapeutic or diagnostic purposes can be administered.
- the pharmaceutical effect starts faster than oral route. Drugs which can not be absorbed easily and degraded in the digestive tract can be given in this way.
- Parenteral administration is preferred when it is desired to act quickly, the patient can not take the drug orally
- the way of administration is determined by the suitability of the vessel, the patient's choices and preferences of the physician.For instance; Although the irritant drugs administered intramuscularly, easily absorbable drugs such as insulin are given by subcutaneously. Effect starts quickly and continues during the desired time. Sterile preparations are produced in clean room conditions for helping to minimize the risk of pyrogenic and particulate matter. Quality assurance of these requirements in sterile manufacturing has great importance and this manufacturing process must be carried out according to the validated production methods and procedures.
- the solution is prepared in class A environment which has a background of class B environment.
- class A environment which has a background of class B environment.
- parenteral drugs are manufactured generally in the form of ready to use syringes or vials in a single dose or rarely multidose, it can be mentioned two types of production process: Usually the issue depends on the education and behavior of the staff.
- WFI water for injection
- WFI 80-90% of water for injection is loaded into the reactor.
- WFI is cooled gradually 50 ° C then 40 ° C. Cooling is performed by flowing WFI which is passing through opposite direction in the coil .
- the solution is made isotonic or isohydric.Osmotic pressure of the solution is adjusted up to the pressure of body fluids.
- the volume of solution (final volume in the recipe) is completed with water for injection.
- Solution is stirred in accordance with the processes for production program. Dissolved oxygen in the solution is removed by sending nitrogen continuously during stirring.
- the solution preparation process ends when dissolved oxygen completely removed by passing through nitrogen.
- Solution is passed through firstly 0,45 ⁇ then 0.22 ⁇ membrane filter and samples are taken for analysis.lt is filtered in this way and samples are taken for the following in- process controls.
- Sending the inert gas such as nitrogen continuously during the preparation process in the production tank is performed to provide removing oxygen and also mechanical stirring of the solution and mixing gas flow .Thus, a complete dissolution and homogeneity is obtained.
- In-process controls are performed after preparation of the solution.
- the solution is filtered 0.45 ⁇ and 0.22 ⁇ membrane filter with nitrogen respectively.
- Filtered product is sent to filling line storage reactor. Preparation for filling and filling are performed after appropriate analysis results.
- the present invention is formed based on these features of the formulation more detailed below.
- Stable formulation for cancer and supportive care is established by using production methods mentioned above with API I and API II as active ingredients and the following excipients.
- API I and API II forms because of their high solubility.
- the ratio and the order of addition of buffering agents in the manufacturing process is determined to provide dissolving of the combination of the active ingredients.
- Solubilizing and buffering agent in the pharmaceutical form sodium hydroxide is selected from sodium carbonate and derivatives.
- Strong acid or alkali solutions cause damage in the area where they are injected.
- Adjusting the pH is needed to increase the stability of the drug, prevent tissue pain, damage and irritation at the injection site, prevent the growth of microorganisms and increase physiological activity.
- the reason of the pH changing is degradation of drug and substances that contaminated from glass or plastics containers and stoppers. Buffer solutions are used if the drug is degraded out of stable pH range.
- buffering agent must be compatible with the drug.Injectable dosage form is desirable to adjust the pH using a suitable buffering agent. pH of the blood is between 7.3-7.5. The injected solution is at the same pH with plasma to prevent pain and irritation. Blood has a buffer capacity. pH adjusment may not be needed because of rapid dilution when intravenous solutions are injected very slowly
- Priority is the stability of the preparation. This is why the pH of the solution is adjusted to 7.5 to 9.0 which the active agent is stable.
- Chelating agent is added to protect patients from the toxicity of metal ions and make active ingredients stable. These stable combined pharmaceutical form can be applied parenterally, when we prefer to use a chelating agent; as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .For any reason very low concentrations of heavy metals in the environment can accelerate oxidation. Therefore, chelating agents are being used to hold these substances. They generate stable water-soluble complexes.
- a chelating agent as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .
- Isotonicity agent is added to the formula not to cause any damage to the patients' cells.
- Isotonicity agent can be selected as sodium chloride,mannitol and- derivatives in this stable parenteral combined pharmaceutical form.
- Isotonic solutions have equivalent pressure to the osmotic pressure of blood plasma. Hypotonic solution has lower osmotic pressure than the osmotic pressure of the blood plasma and the solution which has more osmotic pressure is called hypertonic solutions.
- Sterile parenteral pharmaceutical preparation is equal to body pH (7.4) or close to it, preferably should be isotonic and pyrogen free.
- the solution is desired to be isotonic to reduce the damage of the parenteral drug to the tissue and maintain the blood electrolyte balance.
- Osmotic pressure of the solution (osmolality) is expressed in units of osmole / kg.
- the solution which has lower osmotic pressure from body fluids or 0.9% NaCl is hypotonic. It causes hemolysis of erythrocytes.
- the solution which has more osmotic pressure from body fluid is hypertonic and it causes constriction of erythrocytes. Any cosolvent or surfactan are not required because of the active substance is dissolved.
- the solvent used during production in unit formula is water for injection and it is suitable for preparing parenteral solutions.
- the raw material of the injection water is deionized water known as WPU.WPU is obtained by distillation by passing through the water heat exchanger at 96 ° C to 102 ° C. Pyrogenic substances substantially purified in this water.
- the Water for Injection (WFI) obtained from the autoclave sterilization with contacting with water vapor.This sterilization is identified SIP (sterilization in place) and the process is carried out in situ sterilization.
- Combined stable aqueous solution comprising API I and API II is filled into glass vials and use pre-filled syringe for parenteral use. Both filtration and terminal sterilization were administered. Parenteral solutions is maintained at 121 0 C for 15-20 minutes in autoclave sterilization.
- Parenteral solutions must be sterile because of directly injected to people. Sterility is absence of living organisms such as bacteria and fungi which are reproduced in standard culture media.Sterilization is the destruction of these organisms.
- Parenteral solutions are kept at 121 ° C during 15 to 20 minutes in autoclave sterilization.
- Parenteral solution that unstable to the heat sterilization is filtered through membrane filters which is made of cellulose esters and derivatives and has undefined pore size . 0.22 ⁇ pore size filters are efficient for the removal of very small organisms.
- Ready to use syringes are small primary packaging containers that made of glass, plastic, polymer or copolymer materials which drug or drug solvent is filled for parenteral purpose.Pre-filled syringe and vial containers should not contain any extractable substances that may change stability and increase toxicity of the product.
- Stability is related to shelf life of the product. Time dependent changing of bacterial or chemical compound in the solution is undesired . Therefore stability enhancers and preservatives are added to the parenteral dosage forms.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention is related to solid, liquid, enteral and parenteral stable combinations of pharmaceutical forms comprising N- [4 - [[(2,4-Diamino-6-pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo-6- pteridinyl) methyl] methylamino] benzoyl] -L- glutamic acid pharmaceutically acceptable salts, particulary monohydrate, sodium and disodium, as active ingredients.
Description
Pharmaceutical dosage forms containing N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid and N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid
Technical field
The invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
methylamino)benzoyl]-L(+)-glutamic acid ) (hereafter refer to as API I) and N-[4-[[(2- Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) (hereafter refer to as API II) or pharmaceutically acceptable salts,particulary
monohydrate,sodium and disodium, as active ingredients.
API I :
State of the Art
The formulation of the invention relates to a pharmaceutical dosage form and its combination which is not exist in Turkey and the world.
It is known that the formulation of 50 mg/ml methotrexate and protein binding methotrexate derivatives is used for the treatment of inflammatory autoimmune diseases,
EP2046332 describes using 50 mg/ml methotrexate for the treatment of inflammatory autoimmune diseases.
EP2046813 describes protein binding methotrexate derivatives and pharmaceutical compositions comprising the methotrexate derivatives. The formulation of the protein binding methotrexate derivative is intended to be used for the treatment of cancer and rheumatic disease.The structural formula which mentioned in the independent claim will be explained in detail in the following;
The object of the invention is to provide the use of the most stable pharmaceutical dosage forms that containing API I and API II combination,indicating a long shelf life, used for preventive and therapeutic purpose,increasing patient compliance.
Description of the invention
The invention relates to solid,liquid,enteral and parenteral stable combinations of pharmaceutical forms comprising N-[4-[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl)
methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) (hereafter refer to as API II) or pharmaceutically acceptable salt as active ingredient.
API I is an antineoplastic drug. However, it is used to treat many other diseases unrelated with cancer in lower doses. It is being used via intravenous and higher doses are being used to treat cancer.
API I is a cycle specific drug that is showing both antineoplastic and immunosuppressant activity .As an antimetabolite it inhibits dihydrofolate reductase enzyme which is responsible for reduction of API II to tetrahydro structure . Reduction of tetrahydro API II decreases the required level of one-carbon groups and accordingly, purines' ,DNA's and cellular protein synthesis is inhibited.
API I is being administered by orally and intravenously. It is well absorbed when given as a low single dose (below 50mg / ml). The absorption is irregular when given above this dosage and it is suitable administering in divided doses. It is completely absorbed when administered by intramuscular injection.
Regarding to API I, the British Pharmacopoeia (BP) is reported that the content is not less than %97 on dry basis and the American Pharmacopoeia (USP) reported that the content is not less than %98 on dry basis.lt is yellow to brown crystallized powder. Practically insoluble in water,chloroform and ether. It dissolves in dilute mineral acids and in dilute solutions of alkali hydroxides and carbonates. It must be protected from light.
API II is a water soluble vitamin B-complex used for oral and parenteral administration. Deficiency can cause various hematological complications including megaloblastic anemia.
API II is a biochemically inactive compound that it is precursor of tetrahydrofolic acid and methyltetrahydrofolate. Tetrahydrofolic acid, methyltetrahydrofolate and other folic acid derivatives are necessary substances to sustain erythropoiesis normally. These substances are needed as cofactors for the synthesis of purine and thymidylate nucleic acid. API II and its derivatives are necessary for the conversion of amino acids to each other.
API II is given by oral and parenteral administration. Peak levels have been seen within 1 hour.
API II is yellow to orange-brown coloured, odorless or very lightly scented crystalline powder.According to British Pharmacopoeia (BP), practically it is insoluble in water and other organic solvents. According to US Pharmacopeia (USP), it is very slightly soluble in water; insoluble in alcohol, acetone, chloroform and ether; rapidly soluble in dilute solutions of alkali hydroxides and carbonates; soluble in hydrochloric acid and sulfuric acid. According to USP pH range of solution for injection is 8-1 1. It must be protected from light and avoided freezing.
Parenteral drugs are given to circulatory system directly or indirectly excepting gastrointestinal system with a syringe as a sterile single dose or multi-dose form of ready to use syringe or vial.The pharmaceutical form is containing N- [4 - [[(2,4-Diamino-6- pteridinyl) methyl] methylamino] benzoyl] -L-glutamic acid (or N- [4 - ((2,4-Diaminopteri pyrimidin-6- ylmethyl) methylamino) benzoyl] -L (+) - glutamic acid) and N- [4 - [[(2- Amino-3,4-dihydro-4-oxo,-6-pteridinyl) methyl] methylamino] benzoyl] -L -glutamic acid (or N- (4- (2-Amino-4-hidroksipteridin-6-ylmethylamino) benzoyl) -L (+) - glutamic acid) or their pharmaceutically acceptable salts, individually and / or in combination.
Production of parenteral solution is comprising the production of small volume parenteral of different volumes of liquid dosage form. Production of parenteral drug can be carried out in the fully automated production line named ready to use syringe filling line.
Parenteral solutions are filled into sterile pre-filled syringe, vial or PVC containers.They are administered by injection . Thus,parenteral solutions may also be called injectable solutions. Injectable solutions must be sterile.The pH of the solution must be equal or close to the pH of body fluids (7.4). Osmolality of the solution must be isosmotic with body fluids or close to them.lt must not contain pyrogen which has bacterial lipopolysaccharide structure and can cause fever (should be apyrogenic ). In addition, the solution must not contain particulate matter (micro or macroparticle).
Parenteral treatment is administering therapeutic agents by other than gastrointestinal system. In this way, fluid and electrolytes, vitamins, sugars, protein, blood or components, vaccines, several drugs for therapeutic or diagnostic purposes can be administered. The pharmaceutical effect starts faster than oral route. Drugs which can not be absorbed easily and degraded in the digestive tract can be given in this way.
There are many advantages of drug administered parenterally. Parenteral administration is preferred when it is desired to act quickly, the patient can not take the drug orally
(unconscious patients),the drug is destroyed by gastro-intestinal fluids and providing local effect and complete bioavailability.
The way of administration is determined by the suitability of the vessel, the patient's choices and preferences of the physician.For instance; Although the irritant drugs administered intramuscularly, easily absorbable drugs such as insulin are given by subcutaneously. Effect starts quickly and continues during the desired time.
Sterile preparations are produced in clean room conditions for helping to minimize the risk of pyrogenic and particulate matter. Quality assurance of these requirements in sterile manufacturing has great importance and this manufacturing process must be carried out according to the validated production methods and procedures.
The solutions sterilized by filtration during the process are prepared in class C
environment. If sterile filtration is not possible,the solution is prepared in class A environment which has a background of class B environment.
Including small and large volume parenteral preparations, filling and other operations of aseptically prepared products are done in class A environment which has a background of class B environment.
Because of parenteral drugs are manufactured generally in the form of ready to use syringes or vials in a single dose or rarely multidose, it can be mentioned two types of production process: Mostly the issue depends on the education and behavior of the staff.
It is loaded to the production vessel according to process flow chart. Usually 85% of the volume of WFI (water for injection) is loaded into the reactor firstly. Then, active substance and excipients are loaded.
80-90% of water for injection is loaded into the reactor. Before loading into the production reactor, WFI is cooled gradually 50 ° C then 40 ° C. Cooling is performed by flowing WFI which is passing through opposite direction in the coil .
The solution is made isotonic or isohydric.Osmotic pressure of the solution is adjusted up to the pressure of body fluids.
The volume of solution (final volume in the recipe) is completed with water for injection.
Control and adjustment of pH is made.
Solution is stirred in accordance with the processes for production program. Dissolved oxygen in the solution is removed by sending nitrogen continuously during stirring.
The solution preparation process ends when dissolved oxygen completely removed by passing through nitrogen.
Solution is passed through firstly 0,45 μπι then 0.22 μπι membrane filter and samples are taken for analysis.lt is filtered in this way and samples are taken for the following in- process controls.
In-process controls;
a) pH
b) Viscosity
c) Particulate matter
d) Osmolality
e) Clarity and homogeneity
Product is transferred to the reactor when in-process control results are in the
specifications.
Sending the inert gas such as nitrogen continuously during the preparation process in the production tank is performed to provide removing oxygen and also mechanical stirring of the solution and mixing gas flow .Thus, a complete dissolution and homogeneity is obtained.
In-process controls are performed after preparation of the solution. When in-process controls correspond to specifications,the solution is filtered 0.45 μιη and 0.22 μπι membrane filter with nitrogen respectively.
Filtered product is sent to filling line storage reactor. Preparation for filling and filling are performed after appropriate analysis results.
The present invention is formed based on these features of the formulation more detailed below.
Detailed description of the invention;
Stable formulation for cancer and supportive care is established by using production methods mentioned above with API I and API II as active ingredients and the following excipients.
Table 1
Also in the present invention the ratio and the order of addition of buffering agents in the manufacturing process is determined to provide dissolving of the combination of the active ingredients. Solubilizing and buffering agent in the pharmaceutical form; sodium hydroxide is selected from sodium carbonate and derivatives. Strong acid or alkali solutions cause damage in the area where they are injected. Adjusting the pH is needed to increase the stability of the drug, prevent tissue pain, damage and irritation at the injection site, prevent the growth of microorganisms and increase physiological activity. The reason of the pH changing is degradation of drug and substances that contaminated from glass or plastics containers and stoppers. Buffer solutions are used if the drug is degraded out of stable pH range. It should be considered that buffering agent must be compatible with the drug.Injectable dosage form is desirable to adjust the pH using a suitable buffering agent. pH of the blood is between 7.3-7.5. The injected solution is at the same pH with plasma to prevent pain and irritation. Blood has a buffer capacity. pH adjusment may not be needed because of rapid dilution when intravenous solutions are injected very slowly
Priority is the stability of the preparation. This is why the pH of the solution is adjusted to 7.5 to 9.0 which the active agent is stable.
Chelating agent is added to protect patients from the toxicity of metal ions and make active ingredients stable. These stable combined pharmaceutical form can be applied parenterally, when we prefer to use a chelating agent; as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, disodium and derivatives .For any reason very low concentrations of heavy metals in the environment can accelerate oxidation. Therefore, chelating agents are being used to hold these substances. They generate stable water-soluble complexes.
In the present invention,solution of the active ingredients combination was prepared.
Isotonicity agent is added to the formula not to cause any damage to the patients' cells. Isotonicity agent can be selected as sodium chloride,mannitol and- derivatives in this stable parenteral combined pharmaceutical form.Isotonic solutions have equivalent pressure to the osmotic pressure of blood plasma. Hypotonic solution has lower osmotic pressure than the osmotic pressure of the blood plasma and the solution which has more osmotic pressure is called hypertonic solutions.
Sterile parenteral pharmaceutical preparation is equal to body pH (7.4) or close to it, preferably should be isotonic and pyrogen free. The solution is desired to be isotonic to reduce the damage of the parenteral drug to the tissue and maintain the blood electrolyte balance. Osmotic pressure of the solution (osmolality) is expressed in units of osmole / kg.
The solution which has lower osmotic pressure from body fluids or 0.9% NaCl is hypotonic. It causes hemolysis of erythrocytes. The solution which has more osmotic pressure from body fluid is hypertonic and it causes constriction of erythrocytes.
Any cosolvent or surfactan are not required because of the active substance is dissolved.
There is no need to use any microbial preservative such as benzyl alcohol because aqueous solution which is containing API I and API II is stable during shelf life.
The solvent used during production in unit formula is water for injection and it is suitable for preparing parenteral solutions. The raw material of the injection water is deionized water known as WPU.WPU is obtained by distillation by passing through the water heat exchanger at 96 ° C to 102 ° C. Pyrogenic substances substantially purified in this water. The Water for Injection (WFI) obtained from the autoclave sterilization with contacting with water vapor.This sterilization is identified SIP (sterilization in place) and the process is carried out in situ sterilization.
Combined stable aqueous solution comprising API I and API II is filled into glass vials and use pre-filled syringe for parenteral use. Both filtration and terminal sterilization were administered. Parenteral solutions is maintained at 121 0 C for 15-20 minutes in autoclave sterilization.
Parenteral solutions that sensitive to heat is sterilized by filtration with defined pore size of membrane filter made of cellulose ester. 0.22 um pore size filters are efficient for removing very small organisms. But the solutions that filled in the ready for use syringe filling line is subjected to sterilization at 121 ° C for 20 minutes like ampoules. After the sterilization process samples are sent to the microbiology.
Parenteral solutions must be sterile because of directly injected to people. Sterility is absence of living organisms such as bacteria and fungi which are reproduced in standard culture media.Sterilization is the destruction of these organisms.
Parenteral solutions are kept at 121 ° C during 15 to 20 minutes in autoclave sterilization. Parenteral solution that unstable to the heat sterilization is filtered through membrane filters which is made of cellulose esters and derivatives and has undefined pore size . 0.22 μπι pore size filters are efficient for the removal of very small organisms.
Ready to use syringes are small primary packaging containers that made of glass, plastic, polymer or copolymer materials which drug or drug solvent is filled for parenteral purpose.Pre-filled syringe and vial containers should not contain any extractable substances that may change stability and increase toxicity of the product.
Stability is related to shelf life of the product. Time dependent changing of bacterial or chemical compound in the solution is undesired . Therefore stability enhancers and preservatives are added to the parenteral dosage forms.
We can provide stable formulation comprising API I and API II together.Also it is possible to market the product separately.
Claims
1. Stable combined pharmaceutical forms comprising as active compounds N-[4-
[[(2,4-Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) or pharmaceutically acceptable salts thereof which use of solid and liquid, enteral and parenteral
2. Use of according to claim 1, as an active compound N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and pharmaceutically acceptable salts thereof, particularly monohydrate, sodium and disodium salts
3. Use of according to claim 2, as active compound N-[4-[[(2-Amino-3,4- dihydro -4- oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L-glutamic acid (or N-(4-(2-
Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) and their pharmaceutically acceptable salts thereof, in particular monohydrate, sodium and disodium salts 4. According to claim 3, as active compound N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2- Amino-3,
4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L- glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)- L(+)-glutamic acid) or pharmaceutically acceptable salts thereof, single and/or combined comprising as pharmaceutical dosage forms
5. Use of according to claim 4, as active compound N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2-
Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L- glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)- L(+)-glutamic acid) or pharmaceutically acceptable salts, use of N-[4-[[(2,4- Diamino-6-pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4- ((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid )
10 mg/ml-50 mg/ml dosage and use of N-[4-[[(2-Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl] -L-glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)-L(+)-glutamic acid) 0, 1 mg/ml - 5 mg/ml dosage
6. According to claim 1, as active compound comprising N-[4-[[(2,4-Diamino-6- pteridinyl)methyl] methylamino] benzoyl]-L- glutamic acid (or N-[4-((2,4-Diamino pteridinyl -6-ylmethyl) methylamino)benzoyl]-L(+)-glutamic acid ) and N-[4-[[(2- Amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-L- glutamic acid (or N-(4-(2-Amino-4- hydroxypteridine-6- ylmethyl amino)benzoil)- L(+)-glutamic acid) or pharmaceutically acceptable salts stable combined pharmaceutical forms which applied parenteral
7. According to claim 6, pharmaceutically acceptable salts stable combined
pharmaceutical forms which applied parenteral, use of chelators as edetic acid or edetate disodium hydrate, sodium, calcium disodium, dipotassium, cobalt, disodium, trisodium, magnesium disodium and their derivatives
8. Chelating agent according to claim 7, use of edetate disodium dihydrate in
particular in the range of %0,005-2 mg/ml
9. According to claim 6, pharmaceutically acceptable salts stable combined
pharmaceutical forms which applied parenteral, use of isotonic agent as sodium chloride, mannitol and derivatives 10. According to claim 9, use of isotonic agent as %0, 1 - 0,9 mg/ml of sodium chloride in particular
11. According to claim 6, pharmaceutically acceptable salts stable combined
pharmaceutical forms which applied parenteral, use of solubilizing and buffering agent as sodium hydroxide, sodium carbonate and their derivatives
12. Solubilizing and buffering agent according to claim 1 1, the use of sodium
hydroxide in particular as solid and solution in the range of % 0, 1-20 mg/ml 13. Use of stable combined pharmaceutical forms according to claim 1, comprising protective agents excluding the use benzyl alcohol due to 'Gasping Syndrome' which leads to death
14. Stable combined pharmaceutical forms according to claim 1, packaged with pre- filled syringe or vial of glass and plastic
15. Stable combined pharmaceutical forms according to claim 1, sterilized by autoclave or filtration 16. Stable combined pharmaceutical forms according to claim 1, put on market as combo-pack (two different pharmaceutical forms presented with one secondary packaging)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR201405970 | 2014-05-28 | ||
| TR2014/05970 | 2014-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015183213A1 true WO2015183213A1 (en) | 2015-12-03 |
Family
ID=52596587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2014/000494 WO2015183213A1 (en) | 2014-05-28 | 2014-12-09 | Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2015183213A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2046813A2 (en) | 2006-07-28 | 2009-04-15 | medac Gesellschaft für klinische Spezialgeräte mbH | Protein-binding methotrexate derivatives, and medicaments containing the same |
| EP2046332A2 (en) | 2006-07-21 | 2009-04-15 | medac Gesellschaft für klinische Spezialgeräte mbH | Concentrated methotrexate solutions |
| US20110280932A1 (en) * | 2010-05-13 | 2011-11-17 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent |
-
2014
- 2014-12-09 WO PCT/TR2014/000494 patent/WO2015183213A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2046332A2 (en) | 2006-07-21 | 2009-04-15 | medac Gesellschaft für klinische Spezialgeräte mbH | Concentrated methotrexate solutions |
| EP2046813A2 (en) | 2006-07-28 | 2009-04-15 | medac Gesellschaft für klinische Spezialgeräte mbH | Protein-binding methotrexate derivatives, and medicaments containing the same |
| US20110280932A1 (en) * | 2010-05-13 | 2011-11-17 | Pacira Pharmaceuticals, Inc. | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent |
Non-Patent Citations (4)
| Title |
|---|
| DULAL C. CHATTERJI ET AL: "Thermal and photolytic decomposition of methotrexate in aqueous solutions", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, no. 4, 1 April 1978 (1978-04-01), pages 526 - 531, XP055180778, ISSN: 0022-3549, DOI: 10.1002/jps.2600670422 * |
| HIGNITE C E ET AL: "SEPARATION AND IDENTIFICATION OF IMPURITIES IN PARENTERAL METHOTREXATE DOSAGE FORMS", CANCER TREATMENT REPORTS, vol. 62, no. 1, 1978, pages 13 - 18, XP008175793, ISSN: 0361-5960 * |
| JOSEPH F. GALLELLI ET AL: "Assay of methotrexate in the presence of its decomposition products and other folic acid analogs", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 56, no. 3, 1 March 1967 (1967-03-01), pages 387 - 389, XP055180854, ISSN: 0022-3549, DOI: 10.1002/jps.2600560317 * |
| VINCKE B J ET AL: "Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 54, no. 3, 15 September 1989 (1989-09-15), pages 181 - 189, XP023736092, ISSN: 0378-5173, [retrieved on 19890915], DOI: 10.1016/0378-5173(89)90095-1 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5522877B2 (en) | Moxifloxacin / sodium chloride preparation | |
| JP7178731B2 (en) | Solid pharmaceutical compositions containing biopterin derivatives and uses of such compositions | |
| JP6892494B2 (en) | Aqueous formulation containing paracetamol and ibuprofen | |
| EP1948133B1 (en) | Argatroban formulation comprising an acid as solubilizer | |
| US9572887B2 (en) | Formulations of bendamustine | |
| TWI544934B (en) | Improved pharmaceutical compositions containing a fluoroquinolone antibiotic drug | |
| CN1203855C (en) | Pharmaceutical solutions for levosimendan | |
| CN104323998A (en) | Ganciclovir liposome combination drug and its large-scale industrial production process and application | |
| CN104302176B (en) | Injectable ibuprofen formulation | |
| CN110464846B (en) | Meloxicam composition, preparation method and application thereof | |
| KR101843613B1 (en) | Pharmaceutical pemetrexed solution | |
| JP2017514924A (en) | Preparation of cyclophosphamide liquid concentrate | |
| EP2666463A1 (en) | Stabilized liquid composition comprising pemetrexed | |
| JP2020125359A (en) | Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof | |
| WO2015183213A1 (en) | Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid | |
| JP2001172183A (en) | Ophthalmic pharmaceutical composition | |
| WO2014083071A1 (en) | Injectable liquid formulation of the combination of tramadol and paracetamol | |
| US20240238275A1 (en) | Hydromorphone formulations for multi-dose products | |
| US12011440B2 (en) | Ready-to-administer hydromorphone formulations | |
| JP2000219628A (en) | Previously mixed injectable composition of alatrofloxacin | |
| WO2014007239A1 (en) | Composition containing amphotericin b | |
| WO2024224308A1 (en) | Liquid parenteral formulations of bilastine free of cyclodextrins | |
| WO2016071784A1 (en) | Compositions comprising finafloxacin and tris | |
| EP2934524B1 (en) | Penethamate veterinary injectable formulations | |
| WO2020077564A1 (en) | Teniposide injection solution having good dilution stability and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14841373 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14841373 Country of ref document: EP Kind code of ref document: A1 |